Stockhouse18 天
Regeneron to Advance Two Factor XI Antibodies into a Broad Phase 3 Program Following ...
TARRYTOWN, N.Y., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive Phase 2 results for two novel monoclonal antibodies targeting distinct ...
The Pharma Letter29 天
ASH 2024: Regeneron presents pozelimab + cemdisiran head-to-head data in PNH
In August last year, the US Food and Drug Administration (FDA) approved Veopoz (pozelimab-bbfg) injection for the treatment of adult and pediatric patients aged one year and older with CD55-deficient ...
搜狐1 个月
波泽利单抗（Veopoz pozelimab）—重塑自身免疫疾病治疗版图
这是 FDA 批准的首个治疗 CHAPLE 病的药物。美国食品药品管理局(FDA) 将其视为同类首创药物。 Pozelimab-bbfg 200mg/mL；稀释后用于皮下或静脉注射的溶液；不含防腐剂。 CD55 缺陷型蛋白质丢失性肠病 (PLE)，也称为 CHAPLE 病。 【作用机制】 Pozelimab-bbfg 是一种针对末端补 ...